StockMirror — Stock Screener

STAR Q1 FY27 Results & Earnings Analysis

Sentiment: Neutral (Confidence: medium)

Earnings Summary

Strides Pharma Science reported steady Q1 FY27 results with 13% YoY revenue growth, driven by strong Ex-US performance (17% YoY). Gross margin expanded 60 bps YoY to 60.9%, but EBITDA margin declined 130 bps YoY due to geopolitical disruptions and higher freight costs. Reported PAT grew 56.7% YoY, including a gain from the Pivot Path divestment. The company is navigating external headwinds with a diversified model. The US business remains soft, but management expects a stronger H2 with new approvals and launches. Capex plans remain disciplined at ₹2.5-3 billion annually.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

The company emphasizes a balanced approach, focusing on portfolio quality and profitability in the US while pursuing growth in Ex-US markets. The objective is to maintain gross margins in the 58-60% range and deliver superior EBITDA margins, translating into sustained EPS and PAT growth.

About Strides Pharma Science Limited

Strides Pharma Science Limited (STAR) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More